Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGAGE phase 3 trial of Genz-112638 in Gaucher disease type 1
NL-OMON35650Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Gaucher disease type 1 (GD1) comparing Genz-112638 with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Safety. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NL-OMON35650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35650.